News and Events

Celebrating CCR Careers: Patricia S. Steeg, Ph.D.

Patricia S. Steeg, Ph.D., who discovered the first metastasis suppressor gene, nm23, announces her retirement.

An illustration of papillomas in the throat

Innovative gene therapy shows promise in treating patients with recurrent respiratory papillomatosis

A clinical trial led by CCR researchers demonstrated the effectiveness of the novel treatment, PRGN-2012, against recurrent respiratory papillomatosis in adults. The results serve as the foundation for an application for accelerated approval to the U.S. Food and Drug Administration (FDA).

Image of the BRCA2 protein with a sliding scale of color indicating the regions containing certain variants. Blue regions contain benign variants, while red regions contain pathogenic regions.

Researchers categorize thousands of BRCA2 mutations as cancerous or benign

Researchers used CRISPR gene editing technology to determine whether over 6,000 variants of BRCA2 were likely to cause cancer.

Nirali Shah elected to the American Society for Clinical Investigation

Nirali N. Shah, M.D., M.H.Sc., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, was elected as a member of the American Society for Clinical Investigation (ASCI). The organization seeks to support the scientific efforts, educational needs, and clinical aspirations of physician-scientists to improve the health of all people. The 2025 newly elected members came from 46 different institutions and represent excellence across the breadth of academic medicine.

Clinical trial researching immunotherapy for solid tumors

A clinical trial led by Danielle M. Pastor, D.O., Ph.D., Assistant Research Physician in the Center for Immuno-Oncology, is researching immunotherapy for adults with advanced solid tumors.

Clinical trial researching combination drug therapy for neuroendocrine carcinomas

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching combination drug therapy for adults with high-grade neuroendocrine carcinomas.

Drug shrinks nerve tumors in adults with neurofibromatosis type 1 in a clinical trial

Until recently, no effective treatments existed for non-cancerous inoperable nerve tumors, called plexiform neurofibroma, in adults. A clinical trial of the drug selumetinib shows it can cause tumor shrinkage and relieve symptoms, such as pain.

Celebrating CCR Careers: Jay A. Berzofsky, M.D., Ph.D.

Jay A. Berzofsky, M.D., Ph.D., a chemist-turned-immunologist who pioneered cancer immunology and immunotherapy strategies, announces his retirement from the NCI.

Empowering others to contribute to rare neuroendocrine tumor research

Lacey Koelling was diagnosed with paraganglioma tumors in 2018, which began to metastasize five years later. She enrolled in an NIH trial to contribute to research on this rare cancer.

An observant patient opens new doors for cancer screening

David Drash enrolled in a CCR clinical trial when he was diagnosed with BAP1 tumor predisposition syndrome (TPDS) in 2022. He noticed that everyone in his family with BAP1 TPDS had white lines on their fingernails; his observation led to the discovery of a new detection tool.

Breadcrumb